Announced its investment in Novato-based Alzheimer's drug developer Lighthouse Pharmaceuticals.
JUN 15, 2026
Clinical-stage biopharmaceutical company developing precision therapeutics for chronic degenerative and inflammatory disorders
Clinical-stage biopharmaceutical company developing precision therapeutics for chronic degenerative and inflammatory disorders. Its lead program, LHP588, is a gingipain inhibitor being studied for P. gingivalis-positive Alzheimer's disease; the company is also advancing gingipain-inhibitor applications for periodontal disease, including a licensed canine periodontal health asset.